| |
No adjuvant CTx
|
Adjuvant CTx
|
Pvalue
|
|---|
|
n
|
181 (61)
|
116 (39)
| |
|
Gender
| | |
0.11
|
|
Male
|
115 (64)
|
84 (72)
|
|
Female
|
66 (36)
|
32 (28)
|
|
Age [years]
|
64 (30 – 88)
|
63 (33 – 83)
|
0.03
|
|
Initial stage of disease (UICC)
| | |
0.53
|
|
I
|
23 (7)
|
9 (8)
|
|
II
|
37 (21)
|
17 (15)
|
|
III
|
56 (32)
|
36 (31)
|
|
IV
|
70 (40)
|
53 (46)
|
|
Site of primary tumor
| | |
0.14
|
|
Colon
|
95 (52)
|
71 (61)
|
|
Rectum
|
86 (47)
|
45 (39)
|
|
CEA level [μg/l)
|
12.6 (0.6 – 2032)
|
18.1 (0.5 – 7606)
|
0.63
|
|
Number of metastases
| | |
0.72
|
|
1
|
99 (55)
|
61 (53)
|
|
> 1
|
82 (45)
|
55 (47)
|
|
Size of largest metastasis
| | |
0.06
|
|
< 5 cm
|
95 (52)
|
48 (41)
|
|
≥ 5 cm
|
86 (48)
|
68 (59)
|
|
Distribution of metastases
| | |
0.08
|
|
Unilobar
|
120 (67)
|
66 (57)
|
|
Bilobar
|
60 (33)
|
55 (43)
|
|
MSKCC clinical risk score
| | |
0.07
|
|
≤ 2
|
111 (61)
|
60 (52)
|
|
> 2
|
69 (39)
|
56 (48)
| |
- Data are presented as n (%) or median (range). CTx, Chemotherapy.
